Coya Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
COYA Nasdaq 8731 https://www.coyatherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Coya Therapeutics Inc

Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023 - Mar 31st, 2023 11:00 am
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results - Mar 29th, 2023 8:01 pm
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study - Mar 29th, 2023 1:00 pm
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer - Mar 27th, 2023 11:00 am
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development - Mar 23rd, 2023 1:15 pm
Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET - Mar 23rd, 2023 11:44 am
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study - Mar 22nd, 2023 1:15 pm
Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients - Mar 21st, 2023 3:38 pm
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar - Mar 21st, 2023 3:24 pm
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302 - Mar 21st, 2023 1:55 pm
Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET - Mar 21st, 2023 11:50 am
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) - Mar 21st, 2023 11:00 am
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases - Mar 20th, 2023 11:00 am
Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET - Mar 9th, 2023 12:00 pm
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier? - Mar 6th, 2023 2:00 pm
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas - Feb 28th, 2023 2:00 pm
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. - Feb 27th, 2023 12:00 pm
Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments - Feb 16th, 2023 2:15 pm
Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate - Feb 15th, 2023 12:13 pm
Coya Therapeutics, Inc. to Present Proof of Concept Clinical Data at Multiple Scientific Conferences Throughout 2023 - Feb 2nd, 2023 2:00 pm